Magic mushrooms and Alzheimer's: What one remarkable case can tell us

Article excerpt

A striking case study suggests psilocybin, the active compound in magic mushrooms, may offer unexpected benefits for Alzheimer's patients, challenging the drug's reputation as a recreational hallucinogen. While a single case cannot prove efficacy, researchers are investigating how psilocybin's effects on neuroplasticity and neuroinflammation might slow cognitive decline. The finding underscores a broader scientific pivot: compounds once dismissed as recreational drugs are now being scrutinized for their potential to treat neurodegenerative diseases. Much larger clinical trials would be needed to determine whether this remarkable case signals a genuine therapeutic avenue or merely an outlier.